Skip to main content
61°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atara Biotherapeutics, Inc.
< Previous
1
2
3
4
Next >
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
February 18, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
February 17, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 07, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
January 26, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
January 24, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
December 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
November 30, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
November 08, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
November 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
November 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
October 28, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
October 13, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
October 04, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 01, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
September 29, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
September 27, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 03, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
September 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
August 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
August 09, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
August 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 02, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
July 01, 2021
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.